01—Abstract
Summary
Summary of the 10-Q filed October 31, 2025. Cited figures are marked; the original filing is the authoritative source.
Omega Healthcare Investors, Inc. reported net income available to common stockholders of $179.7 milliona, or $0.59 diluted per share, for the three months ended September 30, 2025, compared with $111.8 million, or $0.42 diluted per share, a year earlier.
For the nine months, net income available to common stockholders was $425.4 millionb, or $1.39 diluted per share, versus $293.0 million, or $1.14 diluted per share, in the prior-year period. Total revenues were $311.6 million for the quarter and $870.9 million for the nine months. Nareit FFO was $241.8 million for the quarter and $639.1 million for the nine months, compared with $196.1 million and $538.3 million a year earlier.
The company's balance sheet grew over the period. Total assets were $10.6 billionc at September 30, 2025, and total debt was $5.0 billion, representing 48.9% of total capitalization. Operating cash flow was $647.9 million for the nine months.
Omega issued 8.8 million shares through its dividend reinvestment plan and 7.5 million through its at-the-market program during the nine months, and it acquired 66 facilities for $637.9 milliond. In September 2025 it replaced its $1.45 billion revolver with a $2.0 billion revolving credit facility and a $300.0 million delayed draw term loan. In October 2025 it redeemed $600.0 million of 5.250% senior notes at par.
Credit quality remains a key watch item. Maplewood, which is on a cash basis and on non-accrual for interest on its $320 million revolver, paid $15.3 million of contractual rent for the quarter against $17.3 million due. Subsequent to quarter-end, the company entered into a joint venture with affiliates of Saber Healthcare Holdings and agreed to acquire a 9.9% equity interest in Saber for $92.6 million in cash, with closing expected January 1, 2026.
02—Key points
Key Highlights
- Net income available to common stockholders rose to $179.7 million ($0.59 diluted per share) for Q3 2025, up from $111.8 million ($0.42 diluted per share) in Q3 2024.
- Nareit FFO was $241.8 million for Q3 2025 versus $196.1 million in Q3 2024; nine-month Nareit FFO was $639.1 million versus $538.3 million.
- Total revenues were $311.6 million for Q3 2025 versus $276.0 million a year earlier, driven by rental and interest income growth.
- The company acquired 66 facilities for $637.9 million in the first nine months of 2025, with initial cash yields between 9.9% and 10.3%.
- Liquidity was strengthened by a new $2.0 billion revolving credit facility and $300.0 million delayed draw term loan, $737.2 million of cash, and $540.1 million of remaining ATM capacity.
- Maplewood remains a credit concern: it paid $15.3 million of $17.3 million contractual rent in Q3 2025, and its $320 million revolver is on non-accrual status.
- Subsequent events include a joint venture with Saber affiliates (64 facilities, $69.4 million annual contractual rent) and a committed $92.6 million investment for a 9.9% equity interest in Saber.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2025filed October 31, 2025Financial Statements
Q3 FY2025 against Q3 FY2024
| Line item | Q3 FY2025Q3 FY2024 | Change |
|---|---|---|
| Revenue | $311.59M$276.03M | +12.9% |
| Operating Expenses | $165.34M$163.26M | +1.3% |
| Operating Income | $310.31M— | — |
| Interest Expense | $58.12M$54.69M | +6.3% |
| Net Income | $179.72M$111.76M | +60.8% |
| EPS (Basic) | $0.60$0.43 | +39.5% |
| EPS (Diluted) | $0.59$0.42 | +40.5% |
| Shares Outstanding (Basic) | 295.83M262.72M | +12.6% |
| Shares Outstanding (Diluted) | 308.17M275.56M | +11.8% |
05—Questions
Frequently Asked Questions
How did Omega's earnings and FFO change in the third quarter of 2025?
Net income available to common stockholders was $179.7 million, or $0.59 per diluted share, compared with $111.8 million, or $0.42 per diluted share, in the third quarter of 2024. Nareit FFO was $241.8 million, compared with $196.1 million a year earlier. The filing attributes higher rental and interest income largely to acquisitions, loan fundings and lease escalations, along with a $28.3 million gain on assets sold in the quarter.
What is the status of Maplewood and how significant is the exposure?
Maplewood paid $15.3 million of contractual rent for the third quarter of 2025 against $17.3 million due and did not pay $3.2 million of contractual interest on its secured revolving credit facility. The $320 million revolver is on non-accrual status, with an amortized cost basis of $263.6 million. The filing notes that if equity assignments under the Smith estate settlement are not completed, the company may incur a substantial loss up to that amortized cost basis. Maplewood generated 6.7% of total revenues for the third quarter of 2025.
How is Omega funding its growth and managing its debt maturities?
During the first nine months of 2025 the company raised $606.8 million of common equity through its ATM and dividend reinvestment programs and issued $600 million of 5.20% senior notes due 2030. In September 2025 it entered a $2.0 billion revolving credit facility and a $300.0 million delayed draw term loan. It redeemed $600.0 million of 5.250% senior notes at par on October 15, 2025. The filing states that cash, available credit and operating cash flow provide the ability to repay upcoming debt maturities. Total debt was $5.0 billion, with a weighted average interest rate of 4.6% and 95.1% of debt having fixed interest payments after hedging.
What are the main events after the quarter ended September 30, 2025?
In October 2025 the company formed a joint venture with affiliates of Saber Healthcare Holdings to own and lease 64 facilities, issuing about 5.5 million Omega OP Units valued at $222.4 million for a 49% equity interest. It also agreed to acquire a 9.9% equity interest in Saber for $92.6 million in cash, with expected closing on January 1, 2026, and a $20.0 million liquidated damages fee if the transaction is terminated due to the other party's breach. The Board declared a $0.67 per share dividend on October 24, 2025, payable November 17, 2025.
What regulatory and operator risks does the filing highlight?
The filing cites ongoing operator challenges, including staffing shortages, inflation-related cost increases and tariffs. It describes the July 2025 OBBBA law, which includes an estimated $920 billion in Medicaid cuts over the next decade, and a Medicare sequestration that the filing says would require an automatic 4% reduction in Medicare reimbursement rates beginning in 2026 absent further legislative action. Genesis Healthcare filed for Chapter 11 in July 2025 but made all required rent and interest payments in August and September 2025. Twenty operators, representing 18.5% of total revenues for the nine months, are on a cash basis of revenue recognition.
06—Continue